Download
slide1 n.
Skip this Video
Loading SlideShow in 5 Seconds..
PANEL Presentation 4 October 2004 Dr Mark Heffernan CEO PowerPoint Presentation
Download Presentation
PANEL Presentation 4 October 2004 Dr Mark Heffernan CEO

PANEL Presentation 4 October 2004 Dr Mark Heffernan CEO

108 Views Download Presentation
Download Presentation

PANEL Presentation 4 October 2004 Dr Mark Heffernan CEO

- - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

  1. PANEL Presentation 4 October 2004 Dr Mark Heffernan CEO

  2. Opsona’s Rationale • Focused on the development of therapeutics and preventatives for autoimmune and inflammatory diseases • Biopharmaceutical Program: • Two lead drugs: • OPN-101: Preventative and therapeutic for autoimmune diseases • OPN-201:Preventative and therapeutic for autoimmune diseases • Toll-Like Receptor (TLR) Program: in discussion with Pharma/Biotech re drug discovery agreement • Small molecules: including orally available molecules for treatment of immune-mediated diseases • Exclusive option agreement to future technology • Founded in March 2004 with three leading immunologists from Trinity College Dublin

  3. The Opsona Model • The Opsona model: • Mark Heffernan, the University and 3 Academics agree to pursue an idea for biotechnology start-up • Idea shows success and company in negotiations to raise ~€5m A-round finance • ALL WITHIN 9 MONTHS

  4. The Founders Dr Mark Heffernan (Co-Founder and CEO): • Senior management at Metabolic Pharmaceuticals Ltd and Antisense Therapeutics Ltd (Australia) – • R&D and BD background Dr Cormac Kilty (Chairman) • CEO Biotrin International • Chairman Irish BioIndustry Association Prof Kingston Mills (Co-founder and Director): • Professor of Experimental Immunology, TCD, • International reputation in Immune regulation • Product commercialisation with Elan and Chiron Prof Luke O’Neill (Co-founder and Director): • Director of the Biotechnology Institute, TCD • International expert in Toll receptor biology Prof Dermot Kelleher (Co-founder and Director): • Director Dept Clin Med. TCD, • Gastroenterologist/Clinical Trials Expertise, • Technology licensing to Chiron Corp

  5. Outstanding Science • Founders are international opinion leaders in basic and clinical research. • Over 500 papers - Nature, Science, J. Exp Med., JBC, Lancet, NEJM, Scientific American • Extensive industry collaborations • >€15m in funding and > 40 lab staff • Intellectual property and proprietary skills in immunomodulation - Hot area! • Two lead drugs – with proof of principle animal experiments established • Rich Pipeline of drugs and novel therapeutic approaches • Significant partnering interest from Pharma and Biotech companies

  6. Company Development

  7. The Model Flow-Chart November/December 2003: MH talks with three key academics December 15th 2003: TCD agrees to undertake feasibility study with MH January 2004: Feasibility Commences MH appoints Bus Dev Consultants February 2004: Receive €30k grant from EI (50% cost of study) Technology Assessment begins March 2004: Opsona Incorporates as a Pvt Ltd company in Ireland Business Plan commenced April 2004: Chairman appointed – Irish Industry Leader June 2004: BPlan complete, VC approached. MH attends major International Biotech Conference, meets with key Industry players

  8. The Model Flow-Chart July 2004: International VCs Approached Syndicate taking shape August 2004: Clinical plan commences – contract key clinicians and consulting companies Negotiations with TCD over License/Option commence October 2004: Development of investor syndicate Clinical plan complete December 2004: Close fundraising & commence operations

  9. Summary Opsona: • start-up company with: • world-leading technology • key scientific founders • rich pipeline • complete proof-of-principle animal experiemts with outstanding data with lead compound, OPN-101 • Clinical trial to commence in 2005 • Program to partner with Biotech/Pharma in 2004/2005 • To succeed: • Get to know everyone fast! • Surround yourself with experienced opinion leaders and advisors • Have story right before approaching VCs • Have access to enough funds for feasibility • Set tight milestones and deadlines

  10. Contact For investment and general enquiries contact: Dr Mark Heffernan, CEO Opsona TherapeuticsLtd, The O’Reilly Institute, Trinity College Dublin, Dublin 2 email: heffernan@opsona.com Ph:+353 (0) 876 434 766, Fax: +353 1 679 8039